Cytokinetics Inc (NASDAQ: CYTK) is -37.09% lower on its value in year-to-date trading and has touched a low of $29.31 and a high of $61.38 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $33.11 in the last trading session, with the day’s loss setting it -31.06%.
Currently trading at $2.05M, the stock is 3.50% and -0.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing 1126794% at the moment leaves the stock -24.97% off its SMA200. CYTK registered -27.91% loss for a year compared to 6-month loss of -30.61%. The firm has a 50-day simple moving average (SMA 50) of $34.211 and a 200-day simple moving average (SMA200) of $45.19365.
The stock witnessed a 11.07% gain in the last 1 month and extending the period to 3 months gives it a -22.28%, and is 3.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.52% over the week and 3.88% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $4.05B and $19.22M in sales. Profit margin for the company is -3201.47%. Distance from 52-week low is 15.69% and -44.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-125.03%).
The EPS is expected to shrink by -8.95% this year
484.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 120.61% of the company’s shares. The shares outstanding are 119.22M, and float is at 116.73M with Short Float at 12.00%. Institutions hold 119.71% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317 of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 10.5485 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 10.4702 and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on Jun 17 ’25 at a price of $32.91 per share for a total of $65820.0. Following the sale, the insider now owns 0.14 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Jun 16 ’25 that Blum Robert I (President & CEO) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Jun 16 ’25 and was made at $33.80 per share for $0.17 million. Following the transaction, the insider now directly holds 0.4 million shares of the CYTK stock.
